FOXO4-DRI vs PNC-27
FOXO4-DRI and PNC-27 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: FOXO4-DRI is 46-residue all-d retro-inverso peptide, while PNC-27 is membranolytic fusion peptide (32 residues): p53-derived domain + membrane-penetrating leader — different molecular classes with different handling consequences; they call for different primary diluents (sterile water (usp grade) versus sterile water for a stock, then dilution into assay buffer); their leading degradation routes differ (deamidation at the asn-gly motif in the sequence for FOXO4-DRI, aggregation of the amphipathic chain at the air-liquid interface or high concentration. for PNC-27), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
FOXO4-DRI — origin
FOXO4-DRI was designed in the laboratory of Peter de Keizer (Erasmus University Medical Center) and published in Cell in 2017 (Baar et al.). It mimics the region of the transcription factor FOXO4 that binds p53, but is built from D-amino acids in reversed order — a retro-inverso design that keeps the side-chain layout while making the backbone unrecognisable to proteases. A cationic, arginine-rich tail derived from the HIV-TAT cell-penetrating sequence carries it into cells.
PNC-27 — origin
PNC-27 is a designed 32-residue peptide fusing a p53-derived region that binds HDM-2 with a membrane-penetrating leader sequence. It is studied strictly in vitro for a reported ability to form pores in the membranes of cancer cells that display HDM-2 at their surface, while reportedly sparing normal cells.
FOXO4-DRI research themes
The founding study showed that senescent cells rely on FOXO4 holding p53 in the nucleus. Interfering with that interaction caused p53 nuclear exclusion and intrinsic apoptosis selectively in senescent cells in culture (Baar et al., Cell 2017).
The same study examined doxorubicin-induced senescence, fast-ageing XpdTTD/TTD mice and naturally aged mice, reporting changes in fur density, fitness and renal markers.
Studied in hydrogen-peroxide-induced senescent TM3 Leydig cells and aged mice for effects on the testicular microenvironment (Zhang et al., Aging 2020).
At 25 µM in vitro it removed a large share of late-passage (senescent-enriched) human chondrocytes while sparing early-passage cells, without improving cartilage-forming capacity (Huang et al., Front Bioeng Biotechnol 2021).
PNC-27 research themes
Studied for binding HDM-2 displayed on the surface of certain cancer cells in vitro.
Examined for forming transmembrane pores that lead to lysis of targeted cells in culture.
Investigated for a reported preference for tumour cells over normal cells in preclinical cell-culture models.
FOXO4-DRI handling
- Let the vial reach room temperature before opening.
- Add diluent gently down the vial wall and swirl; do not vortex.
- Use low-bind polypropylene rather than glass for dilutions — the cationic tail adsorbs to glass.
- Protect solutions from light.
PNC-27 handling
- For laboratory in-vitro use only — this compound is studied strictly in cell-culture research.
- Prepare a stock and dilute into the assay system rather than dissolving at high concentration.
- Aliquot and refrigerate; prepare fresh working dilutions.
Both third-party tested
Every Popular Peptides batch of FOXO4-DRI and PNC-27 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
FOXO4-DRI reference
Related comparisons
FOXO4-DRI and PNC-27 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.